Cargando…
Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients
AIM: Gliomas represent the most frequent neoplasm of the central nervous system. Unfortunately, surgical cure of it is practically impossible and their clinical course is primarily determined by the biological behaviors of the tumor cells. The aim of this study was to investigate the correlation of...
Autores principales: | Zhang, Mingyu, Song, Tao, Yang, Liang, Chen, Ruokun, Wu, Lei, Yang, Zhuanyi, Fang, Jiasheng |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2633002/ https://www.ncbi.nlm.nih.gov/pubmed/19108713 http://dx.doi.org/10.1186/1756-9966-27-85 |
Ejemplares similares
-
FRAT1 Enhances the Proliferation and Tumorigenesis of CD133(+)Nestin(+) Glioma Stem Cells In Vitro and In Vivo
por: Guo, Geng, et al.
Publicado: (2020) -
Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines
por: Veselska, Renata, et al.
Publicado: (2008) -
CD133 Expression and Identification of CD133/nestin Positive Cells in Rhabdomyosarcomas and Rhabdomyosarcoma Cell Lines
por: Sana, Jiri, et al.
Publicado: (2011) -
Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis
por: Wu, Bin, et al.
Publicado: (2015) -
Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas
por: Wu, Xing, et al.
Publicado: (2016)